Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations-MedSci.cn - 梅斯（MedSci）

Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations

Zhao, BH; Xing, H; Ma, WB

Zhao, BH (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing 100730, Peoples R China.

JOURNAL OF THORACIC ONCOLOGY, 2022; 17 (9): E76

科室
- - 订阅+
  - 更多科室
工具
服务